PMN ProMIS Neurosciences

$PMN They have a differentiated approach compared to $ABOS. If you do just a little research you’ll see they target a different therapeutic approach. Great buying opportunity. One door has definitely closed but another remains open.

$PMN $PMN When $LLY and $BIIB works with IgG1 and ProMIS hat the same isotype target but 0 ARIA why would someone compare $ABOS versus Promis ? Soon after unblinding it will show ProMIS is the best AD in class!

$PMN hard to have any faith here after the $ABOS debacle. there may be some differences between the drugs but both have the same basic mechanism (removing toxic oligomers). I dont think removing plaque or oligomers is really going to do squat for alzheimers. lecamamab for example probably does almost nothing in the real world

$PMN ProMIS Neurosciences (PMN) plummeted more than 70% to $3.31 due to a devastating sector-wide sympathy sell-off triggered by the clinical failure of a direct competitor. ABOS 's ALTITUDE IS THE EXACT SAME DRUG . I TOLD U SO 50 TIMES, GET THE HELL OUT !!!!!!!!!!!!!

$PMN Same target class, but PMN310 appears more selective, with little or no plaque binding so far, meaning: PMN310 was designed to bind a specific shape found on toxic oligomers, and ProMIS says it doesn’t bind plaque or monomers in any meaningful way. "Sabirnetug clearly did act on plaque" causing significant plaque reduction on PET and about 10% ARIA-E. The two antibodies bind differently. Sabirnetug clearly hit plaque (PET reduction plus about 10% ARIA-E). The safety data already differ: 0% ARIA-E for PMN310 versus about 10% for sabirnetug. So the market treating them as the same drug is a simplification.

$PMN $ABOS Remember folks.. PMN310 is designed to selectively target toxic soluble amyloid-beta oligomers rather than large amyloid plaques or healthy proteins. 👇😘 • Encouraging Early Safety Data: An interim Phase 1 analysis reported a low overall rate of amyloid-related imaging abnormalities (ARIA) at 4.4% (consisting of mild, asymptomatic brain microbleeds, or ARIA-H), with no instances of severe brain swelling (ARIA-E). • Comparison to Approved Drugs: Approved anti-amyloid therapies like Leqembi and Kisunla carry higher rates of brain swelling (ARIA-E), ranging from 12% to 24% 😘💎💪👀

$PMN people are crazy selling this while they can hold for 200-300% gain even before data ..no wonder 90% Investirs dnt make money ..hold till Jan 1 st week sell above 10-11$

$PMN bold statement to hire CCO from big competitor like $BIIB and $RHHBY to a small Phase 1b Company Dr. Ivana Rubino must have huge positive faith for the data readout in January 27? She saw more and knows more than all other how to proceed and make PMN310 Precise AD a success! Good luck we are on the right path!

$PMN $ABOS I think abos share holders jump into PMN, they might recover some of the losses...Just sayin imo👇😘💎

$PMN Fools sold because of the ABOS drug failure! If there drug has a minuscule 5 day half life and it binds to plaque instead of the ABOs it is supposed to remove and it binds to any ABO not just misfolded ones no wonder it failed! PMN is a a better drug! Thanks for the cheapies Suckas!

The difference between $PMN and $ABOS is: • 0 cases of ARIA-E • Exclusively mild, asymptomatic ARIA-H • 61% APOE4 carriers, including 11% homozygotes. This aligns with the hypothesis that PMN310 does not exhibit relevant binding to plaque or vascular amyloid. The selective neutralization of a specific toxic oligomer population, without significant binding to plaques or vascular deposits, could influence disease processes while simultaneously reducing ARIA. It is a strong, yet still preliminary, clinical signal.

$PMN right now market is saying their science is of negative value. cash in hand 6$ vs sp 3$

$PMN company has released document backing their science. I am good with that. it would have been better had they done a press release.

$PMN Read out coming to a theater near you.. To be considered a "good" readout that triggers a massive stock rally, the data needs to show: • Biomarker Reductions: A statistically significant drop in Alzheimer's markers like p-tau217 or Abeta in the blood or spinal fluid when comparing patients who took the drug vs. patients who took the placebo. • Cognitive Stabilization: Even subtle signs that the drug slowed cognitive decline over the 12 months using standard mental scales (like CDR-SB). The Bottom Line: While historical biotech averages say there's about a 60% chance of moving to Phase 2, the fact that PMN310 has already checked the box on clean safety metrics means its realistic probability of a positive readout is considered higher than the baseline industry average for a triple digit move from these levels.

$PMN iii. Safety profile: The safety profiles are strikingly different. Acumen reported a 10% incidence of ARIA-E, the more serious form of ARIA associated with plaque-binding antibodies, in line with the two marketed drugs. PMN310’s 6-month blinded interim analysis showed zero cases of ARIA-E across all ApoE genotypes. Clinical efficacy is still to be established, but we believe PMN310’s differentiated design and the clinical evidence to date can set it apart from other Alzheimer’s disease antibodies, sabirnetug included.

$PMN From what I’m observing this morning there was plenty of algo triggered on the buy side. Then it started dropping on less volume ane the algos then sold. I double my position under $3 and will now hold. Where are the 6 analysts commenting on the 70% drop from Thursday’s high? They are pathetic.

🚀 5m ORB Alert: $PMN • Breakout Level: $4.15 • Quality Score: 70/100 • Volume Surge: 222082.0x ⏰ Feed delayed 5 mins! Get live alerts + profit targets at the link in my bio!

$PMN late 2025, ProMIS Neurosciences collaborated with Pentara Corporation to publish a cross-trial meta-analysis in the medical journal Alzheimer's & Dementia: Translational Research & Clinical Intervention • Predicting Clinical Outcomes: The study showed that evaluating a patient's plasma pTau levels at 6 months strongly correlates (a ~0.78 correlation) with their actual cognitive and functional benefits at 12 months. • Amplified Biological Signal: Changes in these pTau numbers were found to be 2.6 times larger and much easier to detect than traditional clinical testing, meaning doctors and researchers can see if a therapy is working much earlier. • Real-World Application: ProMIS is actively using this exact pTau methodology in its ongoing Phase 1b PRECISE-AD clinical trial for its lead antibody candidate, PMN310. Recent 2026 interim data from their trial showed that 68.5% of treated patients saw a favorable decline in their plasma pTau217 numbers over a 6-month period.

$PMN They are driving it down before the big climb. It could drop 7 dollars ,an excellent entry price.

$PMN “Neuroscience has been at the center of my career, and I have had the privilege of working across several areas in which major scientific advances have transformed what is possible for patients,” said Dr. Rubino. “Alzheimer’s disease is perhaps one of the clearest examples: although we have made significant progress, meaningful scientific, clinical and access challenges remain. What attracted me to ProMIS was both the differentiated science behind PMN310 and the broader potential of the company’s approach to targeting toxic misfolded proteins. If the clinical data in the ongoing Alzheimer’s trial continue to be supportive, PMN310 could represent an important next step in Alzheimer’s treatment. I am excited to help translate the science into development and commercial strategies that can ultimately create meaningful value for patients, families and the neuroscience community.” Awesome